Allen Investment Management’s AstraZeneca AZN Stock Holding History

Allen Investment Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,726	Closed	-$911K	–	216
2023 Q3	$911K	Hold	6,726	–	–	0.01%	139
2023 Q2	$963K	Hold	6,726	–	–	0.01%	129
2023 Q1	$934K	Hold	6,726	–	–	0.02%	130
2022 Q4	$912K	Sell	6,726 -401	-6%	-$50.3K	0.01%	130
2022 Q3	$782K	Hold	7,127	–	–	0.01%	132
2022 Q2	$942K	Hold	7,127	–	–	0.02%	131
2022 Q1	$946K	Hold	7,127	–	–	0.01%	141
2021 Q4	$830K	Buy	+7,127	New	+$839K	0.01%	153
2021 Q2	–	Sell	-3,001	Closed	-$298K	–	180
2021 Q1	$298K	Hold	3,001	–	–	﹤0.01%	168
2020 Q4	$300K	Hold	3,001	–	–	0.01%	164
2020 Q3	$329K	Buy	+3,001	New	+$334K	0.01%	148
2014 Q4	–	Sell	-105,000	Closed	-$7.5M	–	227
2014 Q3	$7.5M	Sell	105,000 -145,000	-58%	-$10.6M	0.62%	45
2014 Q2	$18.6M	Buy	+250,000	New	+$18.1M	1.94%	22

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Allen Investment Management's AZN Position: Q4 2023 in Review

Allen Investment Management sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 6,726 shares — an estimated $911K sold.

Allen Investment Management first reported a position in AZN in Q2 2014 and held it in 13 quarters. The position peaked at $18.6M in Q2 2014. 1,131 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

Allen Investment Management reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
Allen Investment Management sold 6,726 AstraZeneca shares in Q4 2023, an estimated $911K.
Allen Investment Management first reported a position in AstraZeneca in Q2 2014 and held it in 13 quarters.
Allen Investment Management's AstraZeneca position peaked at $18.6M in Q2 2014.
1,131 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on Allen Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.